Tokyo, July 11 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000062198) titled 'The effects of alfa-cyclodextrin on endurance capacity and the intestinal environment' on July 10.

Study Type: Interventional

Study Design: Basic Design - Parallel Randomization - Randomized Blinding - Double blind -all involved are blinded Control - Placebo

Primary Sponsor: Institute - Juntendo University

Condition: Condition - Healthy people Classification by malignancy - Others Genomic information - NO

Objective: Narrative objectives1 - The purpose of this study is to assess the effect of alfa-cyclodextrin supplementation on endurance capacity and the intestinal environment of male university long-distance runners. Basic objectives2 - Efficacy

Intervention: Interventions/Control_1 - alfa-cyclodextrin 200 mg/day, 8 weeks Interventions/Control_2 - Placebo 200 mg/day, 8 weeks

Eligibility: Age-lower limit - 18 years-old = Gender - Male Key inclusion criteria - 1. University student1. 2. Male athletes belonging to the track and field club's long-distance division 3. Individuals capable of completing all study procedures, including supplementation and measurements 4. Individuals who fully understand the study after receiving a thorough explanation and have provided written informed consent Key exclusion criteria - 1. Individuals with a history or current diagnosis of severe cardiac, hepatic, renal, or gastrointestinal disease. 2. Individuals with a known allergy to the investigational product (or its ingredients). 3. Individuals currently participating in another clinical trial of a food product or pharmaceutical, or who have participated in one within 4 weeks prior to screening. 4. Individuals who plan to change their club affiliation or competitive discipline, or to suspend their athletic activities (e.g., due to leaves of absence or retirement) during the study period. 5. Individuals who have undergone major surgery (e.g., colonoscopic surgery, cholecystectomy, or gastric bypass) that could affect gastrointestinal structure, function, or study outcomes within 6 months prior to obtaining informed consent. 6. Individuals judged by the principal investigator or sub-investigator to be unsuitable for participation in this study for any other reason. Target Size - 36

Recruitment Status: Recruitment status - Completed Date of protocol fixation - 2025 Year 04 Month 30 Day Date of IRB - 2025 Year 04 Month 30 Day Anticipated trial start date - 2025 Year 05 Month 01 Day Last follow-up date - 2025 Year 08 Month 01 Day

To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000071178

Disclaimer: Curated by HT Syndication.